From Barchart: 2025-05-07 16:20:00

Teva Pharmaceutical (NYSE:TEVA) stock surged over 9% following strong first-quarter earnings and an increased full-year profit forecast. Adjusted earnings were $0.52 per share, beating estimates, with revenue rising 5% to $3.9 billion. Core product sales, like AUSTEDO and AJOVY, drove growth, along with improvements in the generics division.

CEO Richard Francis highlighted Teva’s ninth consecutive quarter of revenue growth, emphasizing the company’s focus on innovation, generics leadership, and operational efficiency. Teva raised its 2025 adjusted EPS guidance to $2.45–$2.65 and narrowed its revenue outlook to $16.8–$17.2 billion, reflecting a strong start to the year.



Read more at Barchart:: Teva Surges 9% on Q1 Beat and Upgraded Earnings Ou…